Nasararmu:
Sorrento ya yi doguwar tafiya daga farawa mai ƙasƙanci zuwa ɗimbin biopharma ganowa da haɓaka maganin canza rayuwa.
2009
An kafa
2013
Kaddarorin Resiniferatoxin (RTX) da aka samu ta hanyar siyan Sherrington Pharmaceuticals Inc.
Fasahar Sadarwar Magunguna ta Antibody (ADC) ta hanyar siyan Concortis Biosystems Corp.
2014
PD-L1 mai ba da lasisi don Babban kasuwar China zuwa Lee's Pharm
2016
Kafa ImmuneOncia JV tare da Yuhan Pharmaceuticals
An samu ZTlido® ta hanyar yawancin hannun jari a cikin Scilex Pharmaceuticals
An samu Bioserv Corporation don ayyukan masana'antar cGMP
Kafa Levena Suzhou Biopharma Co. LTD don sabis na Haɗin Magungunan Antibody (ADC)
2017
An sami dandamalin cutar Oncolytic ta hanyar siyan Virttu Biologics Limited
Kafa Celularity tare da Celgene da United Therapeutics
2018
Samun Sofusa® Tsarin Isar da Lymphatic daga Kimberly-Clark
2019
Semnur Pharmaceuticals
An kafa Scilex Holding don haɓaka haɗin gwiwar Scilex Pharma da Semnur Pharma
2020
Abivertinib mai lasisi na musamman daga ACEA Therapeutics don duk alamun duniya, ban da China
Tsarin gwajin HP-LAMP na musamman mai lasisi daga Jami'ar Columbia don gano coronaviruses da ƙwayoyin cuta na mura.
SmartPharm Therapeutics da aka Samu
2021
Samun ACEA Therapeutics
2022
An Samu Virexhealth